§ Same category · GLP-1 / metabolic peptides
Orforglipron vs Retatrutide
Side-by-side price comparison across every tracked vendor. Updated every 4–6 hours.
Pepticker may earn affiliate commissions (typically 5-20%) from linked vendors. See our Affiliate Disclosure.
Orforglipron
1
vendors tracked
from $23.33/mg
Retatrutide
14
vendors tracked
from $2.90/mg
◎ Cheapest $/mg:Retatrutide at $2.90/mg
Orforglipron
Oral small-molecule GLP-1 agonist
No current listings at 0.024mg.
Retatrutide
Triple GCG/GIP/GLP-1 agonist
B-
Operational$29.00
$2.90/mg
In stockOn sale
B
Operational$54.50
$5.45/mg
In stock▲ 87.9% vs best
B-
Operational$78.00
$7.80/mg
Out of stock▲ 169.0% vs best
B-
Operational$79.00
$7.90/mg
In stock▲ 172.4% vs best
Operational
$93.49
$9.35/mg
In stockOn sale▲ 222.4% vs best
Watch
$103.99
$10.40/mg
In stock▲ 258.6% vs best
Operational
$107.25
$10.72/mg
In stock▲ 269.8% vs best
B-
Operational$109.00
$10.90/mg
In stock▲ 275.9% vs best
Watch
$109.00
$10.90/mg
In stock▲ 275.9% vs best
Watch
$129.99
$13.00/mg
Out of stock▲ 348.2% vs best
Operational
$134.99
$13.50/mg
In stock▲ 365.5% vs best
| Vendor | Grade | Risk | Price | $/mg | Trend | Stock | |
|---|---|---|---|---|---|---|---|
| RetaOneLabs US | B- | Operational | $29.00 On sale | $2.90 | In stock | Buy with code → | |
| Welli Labs US | B | Operational | $54.50 ▲ 87.9% | $5.45 | In stock | Visit → | |
| Purus Peptides US | B- | Operational | $78.00 ▲ 169.0% | $7.80 | Out | Visit → | |
| Lab Sourced US | B- | Operational | $79.00 ▲ 172.4% | $7.90 | In stock | Visit → | |
| One Day Compounds US | B- | Operational | $93.49 On sale ▲ 222.4% | $9.35 | In stock | Visit → | |
| Australian Peptide Store AU | B- | Watch | $103.99 ▲ 258.6% | $10.40 | In stock | Visit → | |
| Australian Peptides AU | B- | Operational | $107.25 ▲ 269.8% | $10.72 | In stock | Visit → | |
| Atomik Labz US | B- | Operational | $109.00 ▲ 275.9% | $10.90 | In stock | Visit → | |
| Solution Peptides US | B- | Watch | $109.00 ▲ 275.9% | $10.90 | In stock | Visit → | |
| Felix Chemical Supply US | B- | Watch | $129.99 ▲ 348.2% | $13.00 | Out | Visit → | |
| Research Peptides Europe EU | A | Operational | $134.99 ▲ 365.5% | $13.50 | In stock | Visit → |
Sort:
Last crawl 2026-05-09Sort:
2026-05-09About Orforglipron
An oral non-peptide GLP-1 receptor agonist in Phase 3 for obesity and type-2 diabetes. Typically sold as capsules in research-compound form.
About Retatrutide
An investigational triple-agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 clinical trials for obesity are ongoing; research-compound version is sold via research-chemical vendors.